In this episode of the Science of Skin podcast, Dr. Ted Lain and Dr. Andrew Alexis discuss trifarotene Cream, a novel fourth-generation retinoid. They explore its mechanism of action, clinical efficacy, and the importance of addressing not only acne lesions but also the psychosocial impacts of acne on patients. The conversation delves into the results of phase three and phase four clinical trials, highlighting ttrifarotene's effectiveness in treating both acne and post-inflammatory hyperpigmentation. The episode emphasizes the need for dermatologists to consider the entire acne journey and the long-term benefits of retinoid therapy for their patients.

To watch this an other episodes, be sure to check out our YouTube page 

Takeaways:

Trifarotene is a novel fourth-generation retinoid. It binds preferentially to the RAR gamma receptor, enhancing its efficacy.

Trifarotene not only treats acne but also improves scarring and pigmentation.

Clinical trials show significant efficacy in both facial and truncal acne.

The psychosocial impact of acne is profound and long-lasting.

Retinoids are foundational in acne treatment regimens. Patients benefit from continued use of retinoids beyond acne clearance.

Phase four studies demonstrate trifarotene's effectiveness in reducing atrophic scars.

Acne-induced hyperpigmentation is a significant concern that needs addressing.

Education about retinoids can improve patient compliance.